RNAi therapeutic strategies for acute respiratory distress syndrome

Melissa L Jagrosse; David A Dean; Arshad Rahman; Bradley L Nilsson

doi:10.1016/j.trsl.2019.07.011

RNAi therapeutic strategies for acute respiratory distress syndrome

Transl Res. 2019 Dec:214:30-49. doi: 10.1016/j.trsl.2019.07.011. Epub 2019 Jul 27.

Authors

Melissa L Jagrosse¹, David A Dean², Arshad Rahman², Bradley L Nilsson³

Affiliations

¹ Department of Chemistry, University of Rochester, Rochester, New York.
² Department of Pediatrics and Neonatology, University of Rochester Medical Center, School of Medicine and Dentistry, University of Rochester, Rochester, New York.
³ Department of Chemistry, University of Rochester, Rochester, New York. Electronic address: bradley.nilsson@rochester.edu.

Abstract

Acute respiratory distress syndrome (ARDS), replacing the clinical term acute lung injury, involves serious pathophysiological lung changes that arise from a variety of pulmonary and nonpulmonary injuries and currently has no pharmacological therapeutics. RNA interference (RNAi) has the potential to generate therapeutic effects that would increase patient survival rates from this condition. It is the purpose of this review to discuss potential targets in treating ARDS with RNAi strategies, as well as to outline the challenges of oligonucleotide delivery to the lung and tactics to circumvent these delivery barriers.

Publication types

Research Support, N.I.H., Extramural
Review

MeSH terms

Animals
Capillary Permeability
Drug Delivery Systems
Gene Transfer Techniques
Humans
Nanoparticles / chemistry
RNA Interference*
Respiratory Distress Syndrome / therapy*

Abstract

Publication types

MeSH terms

Grants and funding